TY - JOUR
T1 - Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals
T2 - results from the South Australian Metastatic Colorectal Cancer Registry
AU - McNeill, David
AU - Karapetis, Christos S.
AU - Price, Timothy J.
AU - Meagher, Philip
AU - Piantadosi, Cynthia
AU - Quinn, Stephen
AU - Roder, David
AU - Padbury, Rob
AU - Maddern, Guy
AU - Townsend, Amanda
AU - Jayawardana, Madawa W.
AU - Roy, Amitesh C.
PY - 2021/1
Y1 - 2021/1
N2 - Background: Studies have reported significant differences in baseline characteristics and outcomes of metastatic colorectal cancer (mCRC) patients when managed in private versus public hospitals. Aims: To compare disease, treatment and survival outcomes of patients with mCRC in public versus private hospitals in South Australia (SA). Methods: Analysis of prospectively collected data from the SA mCRC Registry. Patterns of care and outcome data according to location of care and socioeconomic status based on Index of Relative Socio-Economic Advantage and Disadvantage were analysed. Results: A total of 3470 patients’ data was analysed during February 2006–January 2015. The majority (70%) of patients received treatment in public hospitals. Patients in the upper 50% for Index of Relative Socio-Economic Advantage and Disadvantage score were more likely to receive treatment at a private hospital (41.2% vs 21.56%) compared to <50%. Public patients had higher burden of disease (10.49% vs 7.41%, P = 0.005). Public patients received less treatment compared to the private patients (odds ratio = 0.48 (0.38–0.61), P = 0.01) and rates of surgical resections were lower in public patients. After adjusting for the covariates, public patients survive 1.33 months (P = 0.025) shorter than private patients with follow-up time of 5 years. Patients receiving metastasectomy and more than three lines of treatment were shown to have the greatest survival benefit. Conclusion: Public patients have a higher burden of disease and in comparison are less likely to receive systemic therapy and have lower survival than patients treated in private hospitals.
AB - Background: Studies have reported significant differences in baseline characteristics and outcomes of metastatic colorectal cancer (mCRC) patients when managed in private versus public hospitals. Aims: To compare disease, treatment and survival outcomes of patients with mCRC in public versus private hospitals in South Australia (SA). Methods: Analysis of prospectively collected data from the SA mCRC Registry. Patterns of care and outcome data according to location of care and socioeconomic status based on Index of Relative Socio-Economic Advantage and Disadvantage were analysed. Results: A total of 3470 patients’ data was analysed during February 2006–January 2015. The majority (70%) of patients received treatment in public hospitals. Patients in the upper 50% for Index of Relative Socio-Economic Advantage and Disadvantage score were more likely to receive treatment at a private hospital (41.2% vs 21.56%) compared to <50%. Public patients had higher burden of disease (10.49% vs 7.41%, P = 0.005). Public patients received less treatment compared to the private patients (odds ratio = 0.48 (0.38–0.61), P = 0.01) and rates of surgical resections were lower in public patients. After adjusting for the covariates, public patients survive 1.33 months (P = 0.025) shorter than private patients with follow-up time of 5 years. Patients receiving metastasectomy and more than three lines of treatment were shown to have the greatest survival benefit. Conclusion: Public patients have a higher burden of disease and in comparison are less likely to receive systemic therapy and have lower survival than patients treated in private hospitals.
KW - cancer outcomes private versus public
KW - metastatic colorectal cancer
KW - South Australian Metastatic Colorectal Cancer Registry
UR - http://www.scopus.com/inward/record.url?scp=85100953562&partnerID=8YFLogxK
U2 - 10.1111/imj.14765
DO - 10.1111/imj.14765
M3 - Article
C2 - 31985128
AN - SCOPUS:85100953562
SN - 1444-0903
VL - 51
SP - 69
EP - 77
JO - Internal Medicine Journal
JF - Internal Medicine Journal
IS - 1
ER -